Zevra Therapeutics to Report Second Quarter 2024 Financial Results
Zevra Therapeutics (NASDAQ: ZVRA), a rare disease therapeutics company, has announced it will host a conference call and audio webcast on August 13, 2024, at 4:30 p.m. ET to review its corporate and financial results for the second quarter of 2024. The audio webcast will be accessible through the Investor Relations section of the company's website. Investors can join the meeting via conference call using the provided dial-in numbers. An archive of the webcast will be available for 90 days starting approximately at 5:30 p.m. ET on the same day.
Zevra Therapeutics (NASDAQ: ZVRA), un'azienda che si occupa di terapie per malattie rare, ha annunciato che ospiterà una conferenza telefonica e un'audio webcast il 13 agosto 2024, alle 16:30 ET per rivedere i risultati aziendali e finanziari per il secondo trimestre del 2024. L'audio webcast sarà accessibile attraverso la sezione Relazioni con gli Investitori del sito web dell'azienda. Gli investitori possono partecipare alla riunione tramite conferenza telefonica utilizzando i numeri di accesso forniti. Un'archiviazione della webcast sarà disponibile per 90 giorni a partire da circa le 17:30 ET dello stesso giorno.
Zevra Therapeutics (NASDAQ: ZVRA), una empresa de terapias para enfermedades raras, ha anunciado que llevará a cabo una conferencia telefónica y una transmisión de audio el 13 de agosto de 2024, a las 4:30 p.m. ET para revisar sus resultados corporativos y financieros del segundo trimestre de 2024. La transmisión de audio estará disponible a través de la sección de Relaciones con Inversores en el sitio web de la empresa. Los inversores pueden unirse a la reunión mediante conferencia telefónica utilizando los números de acceso proporcionados. Un archivo de la transmisión estará disponible por 90 días a partir de aproximadamente las 5:30 p.m. ET del mismo día.
Zevra Therapeutics (NASDAQ: ZVRA), 희귀질환 치료제 회사는 2024년 8월 13일 오후 4시 30분 ET에 기업 및 재무 결과를 검토하기 위한 컨퍼런스 콜 및 오디오 웹캐스트를 개최할 것이라고 발표했습니다. 오디오 웹캐스트는 회사 웹사이트의 투자자 관계 섹션을 통해 접근할 수 있습니다. 투자자는 제공된 전화 번호를 사용하여 컨퍼런스 콜에 참여할 수 있습니다. 웹캐스트 아카이브는 같은 날 오후 5시 30분 ET부터 약 90일 동안 이용 가능합니다.
Zevra Therapeutics (NASDAQ: ZVRA), une entreprise de thérapies pour maladies rares, a annoncé qu'elle tiendra une conférence téléphonique et un webcast audio le 13 août 2024 à 16h30 ET pour examiner ses résultats d'entreprise et financiers pour le deuxième trimestre de 2024. Le webcast audio sera accessible via la section Relations avec les investisseurs du site web de l'entreprise. Les investisseurs peuvent rejoindre la réunion par conférence téléphonique en utilisant les numéros d'appel fournis. Un enregistrement du webcast sera disponible pendant 90 jours à partir d'environ 17h30 ET le même jour.
Zevra Therapeutics (NASDAQ: ZVRA), ein Unternehmen für Therapien bei seltenen Krankheiten, hat angekündigt, dass es am 13. August 2024 um 16:30 Uhr ET einen Telefonkonferenz- und Audio-Webcast abhalten wird, um seine Unternehmens- und Finanzergebnisse für das zweite Quartal 2024 zu überprüfen. Der Audio-Webcast wird über den Bereich Investor Relations der Unternehmenswebsite zugänglich sein. Investoren können an dem Meeting über die bereitgestellten Einwahlnummern teilnehmen. Eine Archive der Webcast wird ab ungefähr 17:30 Uhr ET am selben Tag für 90 Tage verfügbar sein.
- None.
- None.
Audio Webcast schedule to be held on August 13, 2024 at 4:30 p.m. ET
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and audio webcast on Tuesday, August 13, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the second quarter of 2024.
The link to the audio webcast will be accessible via the Investor Relations section of the Company’s website, https://investors.zevra.com/.
To join the meeting by conference call, use the dial-in information below.
- (800) 225-9448 (U.S.)
- +1 (203) 518- 9708 (International)
- Conference ID: ZVRAQ224
An archive of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET, on August 13, 2024, at https://investors.zevra.com/.
About Zevra Therapeutics
Zevra Therapeutics is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Expanded access programs are made available by Zevra Therapeutics and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy as published on its website at www.zevra.com. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion.
For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2023, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Russo Partners Contacts
Adanna G. Alexander, Ph.D.
+1 (646) 942-5603
adanna.alexander@russopartnersllc.com
Ignacio Guerrero-Ros, Ph.D.
+1 (646) 942-5604
ignacio.guerrero-ros@russopartnersllc.com
FAQ
When will Zevra Therapeutics (ZVRA) report its Q2 2024 financial results?
How can investors access Zevra Therapeutics' (ZVRA) Q2 2024 earnings call?
How long will the archive of Zevra Therapeutics' (ZVRA) Q2 2024 earnings webcast be available?
